Study #2021-0369
A Phase 1b, open label, global, multicenter, dose determination, randomized dose expansion study to determine the maximum tolerated dose, assess the safety and tolerability, pharmacokinetics and preliminary efficacy of iberdomide (CC-220) in combination withR- CHOP-21 and CC-99282 in combination with R-CHOP-21 for subjects with previously untreated, poor risk (IPI 3 to 5), aggressive B-cell lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
CC-220, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, CC-99282
Description
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21.
Information and next steps
Disease:
Lymphoma, B-Cell
Study phase:
I
Physician name:
Jason Westin
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.